GENI Genius Sports Limited Forecast, Technical & Fundamental Analysis
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries... Show more
GENI is expected to report earnings to fall 63.05% to -7 cents per share on August 11
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.14
Q4'25
Missed
by $0.12
Q3'25
Missed
by $0.12
Q2'25
Missed
by $0.20
The last earnings report on May 07 showed earnings per share of -20 cents, missing the estimate of -7 cents. With 5.15M shares outstanding, the current market capitalization sits at 1.77B.
A.I.dvisor indicates that over the last year, GENI has been loosely correlated with CARG. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GENI jumps, then CARG could also see price increases.
Aroon Indicator for GENI shows an upward move is likely
GENI's Aroon Indicator triggered a bullish signal on June 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 198 similar instances where the Aroon Indicator showed a similar pattern. In of the 198 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 02, 2026. You may want to consider a long position or call options on GENI as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GENI moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where GENI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GENI turned negative on June 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GENI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.542) is normal, around the industry mean (10.785). P/E Ratio (0.000) is within average values for comparable stocks, (32.465). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (32.157). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.409) is also within normal values, averaging (69.742).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
